Alnylam Pharmaceuticals, INC.

Biopharmaceutical company

Based in MA

🤖

AI Overview

With $1.4M in lobbying spend across 30 quarterly filings, Alnylam Pharmaceuticals, INC. is a significant lobbying presence.

$1.4M
Total Lobbying Spend
30
Quarterly Filings
1
Lobbying Firms Used
10
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$60K
2019$90K
2020$90K
2021$210K
2022$200K
2023$200K
2024$300K
2025$240K

Lobbying Firms

TODD STRATEGY GROUP

What They Lobby For

  • Medicare coverage and reimbursement.
  • COVID-19 Response.
  • Medicare coverage and reimbursement. Home infusion.
  • Medicare coverage and reimbursement. Home infusion. Part B Rebates.
  • Medicare coverage and reimbursement. Home infusion. H.R.5376 - Build Back Better Act. H.R.3684 - Infrastructure Investment and Jobs Act.
  • Medicare coverage and reimbursement. Home Infusion. H.R.5376 - Build Back Better Act.
  • Medicare coverage and reimbursement. Home Infusion. H.R.5376 - Build Back Better Act. FDA regulation of platform technologies.
  • Medicare coverage and reimbursement. Home Infusion. H.R.5376 - Inflation Reduction Act of 2022. FDA regulation of platform technologies.
  • Medicare and Medicaid Issues. MINI Act. ORPHAN Act. Food and Drug Omnibus Reform Act of 2022.
  • Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.